# Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea

> **NCT03447821** · PHASE2 · COMPLETED · sponsor: **Cosmo Technologies Ltd** · enrollment: 40 (actual)

## Conditions studied

- Infectious Diarrhoea

## Interventions

- **DRUG:** 400 mg Rifamycin SV dosage
- **DRUG:** 800 mg Rifamycin SV dosage
- **DRUG:** 1200 mg Rifamycin SV dosage

## Key facts

- **NCT ID:** NCT03447821
- **Lead sponsor:** Cosmo Technologies Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03447821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03447821, "Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03447821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*